Medivation Cancer Drug Fuels Beat, Swings To Profit

By | August 8, 2014

Scalper1 News

Medivation (MDVN) stock rose to a five-month high Friday after the biotech company soundly beat Q2 estimates late Thursday and turned the corner to profitability. Medivation stock was up nearly 11.5% in morning trading on the stock market today, near 84 and within hailing distance of its all-time high of 88.20, touched on Feb. 25. Medivation reported a profit of 60 cents a share, reversing a year-earlier loss and more than doubling analysts’ Scalper1 News

Scalper1 News